Company profile: Coeptis Therapeutics
1.1 - Company Overview
Company description
- Provider of cell therapy platforms: SNAP-CAR uses monoclonal antibodies with benzyl guanine linkers for tunable oncology or autoimmune treatment; GEAR-NK is a modified NK therapy co-administered with targeted antibodies; cord blood-derived HSPCs generate NK cells; and an unmodified NK program enables allogeneic therapy without HLA matching, currently in Phase 1 for anti-viral treatments.
Products and services
- GEAR-NK: A clinical-grade modified natural killer cell therapeutic optimized for co-administration with targeted antibodies to boost tumor cytotoxicity and sustain immune surveillance
- SNAP-CAR: A modular cell therapy platform leveraging monoclonal antibodies conjugated to a benzyl guanine linker, enabling recognition by custom SNAP-CAR cells for tunable oncology or autoimmune treatment
- Unmodified Immune Effector Cell Program: An allogeneic-ready platform generating natural killer cells without standard HLA matching, now in Phase 1 clinical trials for anti-viral treatments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Coeptis Therapeutics
Organogenesis
HQ: United States
Website
- Description: Provider of regenerative medicine products, including PuraPly MZ, a micronized wound matrix made from purified porcine collagen to support healing in complex surgical wounds by inhibiting excess MMPs, and PuraForce, a purified collagen matrix used for tendon reinforcement during tendon repair surgeries, providing biomechanical strength and support without bulk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Organogenesis company profile →
ArsenalBio
HQ: United States
Website
- Description: Provider of programmable CAR T-cell therapies for solid tumors, using synthetic biology to engineer T cells, including AB-1015 for ovarian cancer with dual antigen-sensing logic gating, AB-2100 for kidney cancer with potency enhancements, and the AB-3000 series for prostate cancer; collaborates with Bristol Myers Squibb and Genentech to advance next-generation T-cell therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArsenalBio company profile →
Advanced Cell Technology
HQ: United States
Website
- Description: Provider of stem cell-based regenerative therapies, including human embryonic stem cell-derived retinal pigment epithelial (RPE) therapy for retinal degenerative diseases such as Stargardt's disease and dry age-related macular degeneration; a hemangioblast (HG) platform for blood and cardiovascular diseases with CHA Biotech; and myoblast autologous adult stem cell therapy for heart failure, advanced cardiac disease, myocardial infarction, and ischemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advanced Cell Technology company profile →
TeraImmune
HQ: United States
Website
- Description: Provider of cell therapeutics for autoimmune diseases and immune-related disorders, using donor-derived regulatory T (Treg) cells to make Treg cells for hemophilia, multiple sclerosis, and graft-versus-host disease from stem cell transplantation, enabling the healthcare industry to suppress the unwanted immune.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TeraImmune company profile →
Vericel
HQ: United States
Website
- Description: Provider of therapies for cartilage repair and burn care, including MACI for knee cartilage defects using the patient’s own cultured cells on a collagen membrane; Epicel, a permanent skin replacement for patients with deep dermal or full-thickness burns covering a large percentage of their body; and NexoBrid, a bromelain-based enzymatic solution for eschar removal in adults with deep partial- and/or full-thickness thermal burns.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vericel company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Coeptis Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Coeptis Therapeutics
2.2 - Growth funds investing in similar companies to Coeptis Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Coeptis Therapeutics
4.2 - Public trading comparable groups for Coeptis Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →